← Back to Search

Vasodilator

PAH Therapies for Pulmonary Arterial Hypertension (CARE PAH Trial)

Phase 4

Waitlist Available

Research Sponsored by Actelion

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 years

Awards & highlights

CARE PAH Trial Summary

This trial is measuring how long it takes for PAH patients to die or be hospitalized due to PAH.

Eligible Conditions

Pulmonary Arterial Hypertension

CARE PAH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to Death due to Pulmonary Arterial Hypertension (PAH) or First Hospitalization due to PAH

Time to all Cause Death

Secondary outcome measures

Change from Baseline in 6-minute Walk Distance (6MWD)

Change from Baseline in Health Related Quality of Life Assessed by European Quality of Life (EuroQoL) Group, 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)

Change from Baseline in Health-Related Quality of life Status as Assessed by 36-item Short-Form Health Survey (SF-36) v2 Acute Questionnaire

+23 more

CARE PAH Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with PAHExperimental Treatment1 Intervention

Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a routine clinical setting, either as first-line therapy, as replacement therapies, as concomitant with other PAH therapies, or have already been receiving macitentan 10 milligrams (mg) for at least 3 months prior to the index date. The primary data source for this study will be the medical records of each participant.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ActelionLead Sponsor

191 Previous Clinical Trials

35,461 Total Patients Enrolled

66 Trials studying Pulmonary Arterial Hypertension

15,753 Patients Enrolled for Pulmonary Arterial Hypertension

Actelion Clinical TrialStudy DirectorActelion

13 Previous Clinical Trials

799 Total Patients Enrolled

2 Trials studying Pulmonary Arterial Hypertension

147 Patients Enrolled for Pulmonary Arterial Hypertension

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the desired outcome of this research endeavor?

"This medical study seeks to ascertain Time to all Cause Death over a six-year period. Secondary objectives include assessing Change from Baseline in N-terminal-pro-hormone Brain Natriuretic Peptide (NT-proBNP), Change from Baseline in Health Related Quality of Life Assessed by Patient Health Questionnaire-8 (PHQ-8) item Total Score, and establishing the timeline for Time to All -Cause Death Based on the Risk Category Determined by REVEAL Lite 1."

Answered by AI

Are PAH Therapies associated with any adverse reactions?

"There is a significant amount of evidence confirming the safety of PAH Therapies, thus it was assigned a rating of 3."

Answered by AI

Is there a significant number of healthcare facilities currently conducting this research in Canada?

"Patients can be enrolled in this healthcare trial at Washington University School of Medicine, Cleveland Clinic Florida, and Kentuckiana Pulmonary Associates; there are 24 other sites available for participation."

Answered by AI

What is the upper bound of enrollees for this clinical experiment?

"In order for this trial to be complete, 3000 eligible patients need to participate. Those interested in joining can find locations such as Washington University School of Medicine and Cleveland Clinic Florida offering the study."

Answered by AI

Is participation in this experiment still possible for those seeking treatment?

"Affirmative. According to the information provided on clinicaltrials.gov, this medical trial was first uploaded October 14th 2021 and recently updated November 7th 2022. 3000 participants will be enrolled from 27 distinct sites across the country."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

2021. "A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04955990.